

Sergio Manzano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/879125/publications.pdf>

Version: 2024-02-01

113
papers

3,258
citations

196777

29
h-index

190340

53
g-index

120
all docs

120
docs citations

120
times ranked

5129
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 881-891.	1.8	6
2	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. <i>Lancet, The</i> , 2021, 397, 199-207.	6.3	164
3	Impact of a Mobile App on Paramedics' Perceived and Physiologic Stress Response During Simulated Prehospital Pediatric Cardiopulmonary Resuscitation: Study Nested Within a Multicenter Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e31748.	1.8	6
4	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 408-416.	0.4	3
5	Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 696-705.	0.8	28
6	P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 31-42.	1.4	37
7	Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. <i>International Journal of Cardiology</i> , 2020, 301, 200-206.	0.8	26
8	Caregivers' Willingness to Accept Expedited Vaccine Research During the COVID-19 Pandemic: A Cross-sectional Survey. <i>Clinical Therapeutics</i> , 2020, 42, 2124-2133.	1.1	56
9	Incidence, prognosis and predictors of heart failure after acute myocardial infarction. <i>REC: CardioClinics</i> , 2020, 55, 8-14.	0.1	5
10	Incidencia anual de trombosis del stent confirmadas y factores clínicos predictores en pacientes con SCA tratados con ticagrelor o prasugrel. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 298-304.	0.6	4
11	Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 298-304.	0.4	1
12	Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry. <i>Current Medical Research and Opinion</i> , 2019, 35, 2035-2041.	0.9	10
13	A mobile device application to reduce medication errors and time to drug delivery during simulated paediatric cardiopulmonary resuscitation: a multicentre, randomised, controlled, crossover trial. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 303-311.	2.7	36
14	Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13161.	1.7	5
15	Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 381-391.	1.0	16
16	Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry. <i>Current Medical Research and Opinion</i> , 2019, 35, 1463-1471.	0.9	3
17	Utilidad de la puntuación PARIS para evaluar el equilibrio isquémico-hemorrágico con ticagrelor y prasugrel tras un síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 215-223.	0.6	6
18	Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome. <i>REC: CardioClinics</i> , 2019, 54, 148-156.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Asociación entre las escalas de riesgo isquémico y hemorrágico y el uso de los nuevos inhibidores del P2Y 12 en pacientes con síndrome coronario agudo. Revista Espanola De Cardiologia, 2018, 71, 538-544.	0.6	5
20	Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients. Revista Espanola De Cardiologia (English Ed), 2018, 71, 829-836.	0.4	8
21	Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12907.	1.7	13
22	Inconclusive Exercise Stress Echocardiography in Patients With Chest Pain: Prevalence and Clinical Determinants. Revista Espanola De Cardiologia (English Ed), 2018, 71, 406-408.	0.4	3
23	Causas y predictores de muerte de los pacientes con fibrilación auricular que inician tratamiento con anticoagulantes orales directos. Revista Espanola De Cardiologia, 2018, 71, 500-503.	0.6	0
24	Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y 12 Inhibitors in Patients With Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2018, 71, 538-544.	0.4	4
25	Impacto pronóstico diferencial del infarto de miocardio comparado con la gravedad de la hemorragia sobre la mortalidad en pacientes contemporáneos con síndrome coronario agudo. Revista Espanola De Cardiologia, 2018, 71, 829-836.	0.6	9
26	Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry. International Journal of Cardiology, 2018, 273, 29-33.	0.8	15
27	Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry. Thrombosis Research, 2018, 167, 142-148.	0.8	19
28	Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke. Future Cardiology, 2018, 14, 31-37.	0.5	5
29	Comparación de escalas de riesgo hemorrágico en pacientes con fibrilación auricular no valvular que inician anticoagulantes orales de acción directa. Revista Espanola De Cardiologia, 2017, 70, 878-880.	0.6	2
30	Impacto de las enfermedades autoinmunitarias en el tratamiento y el pronóstico del síndrome coronario agudo. Revista Espanola De Cardiologia, 2017, 70, 1145-1147.	0.6	0
31	Evaluation of the CRUSADE Risk Score for Predicting Major Bleeding in Patients with Concomitant Kidney Dysfunction and Acute Coronary Syndromes. CardioRenal Medicine, 2017, 7, 179-187.	0.7	1
32	Comparison of Risk Prediction With the <sc>CKD&EPI</sc> and <sc>MDRD</sc> Equations in Non&sc>ST</sc> Segment Elevation Acute Coronary Syndrome. Clinical Cardiology, 2016, 39, 507-515.	0.7	17
33	La puntuación SAMe-TT2R2 no predice el tiempo en rango terapéutico tras un ingreso por insuficiencia cardiaca aguda en pacientes con fibrilación auricular. Revista Espanola De Cardiologia, 2016, 69, 453-454.	0.6	6
34	SAMe-TT2R2 Score: Useful in All Patients With Nonvalvular Atrial Fibrillation? Response. Revista Espanola De Cardiologia (English Ed), 2016, 69, 799.	0.4	0
35	Puntuación SAMe-TT2R2: ¿es útil en todos los pacientes con fibrilación auricular no valvular? Respuesta. Revista Espanola De Cardiologia, 2016, 69, 799.	0.6	0
36	Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes With Early Implementation of the ACC/AHA Guidelines Risk Score to Predict In-Hospital Mortality and Major Bleeding in Acute Coronary Syndromes. American Journal of Cardiology, 2016, 117, 1047-1054.	0.7	21

#	ARTICLE	IF	CITATIONS
37	Validation of a New Risk Score for Predicting Post-discharge Cardiovascular Events in Patients With Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 338-340.	0.4	0
38	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 134-140.	0.4	4
39	Validaci3n de una nueva escala de riesgo para predecir eventos cardiovasculares poshospitalizaci3n en pacientes con s3ndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 338-340.	0.6	1
40	Repercusiones en la posolog3a de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la funci3n renal de los pacientes con fibrilaci3n auricular e insuficiencia cardiaca aguda reciente. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 134-140.	0.6	9
41	SAMe-TT2R2 Score Does Not Predict Time in Therapeutic Range in Atrial Fibrillation Patients After Hospitalization for Acute Decompensated Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 453-454.	0.4	1
42	Comparison between type-2 and type-1 myocardial infarction: clinical features, treatment strategies and outcomes. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 15-22.	0.2	35
43	Aortic valve haematoma as a complication after coronary angiography: a clinical case with spontaneous resolution. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 1043.	0.5	0
44	sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2015, 45, 899-905.	1.7	19
45	Major bleeding risk prediction using Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease equations in acute coronary syndrome. <i>European Journal of Clinical Investigation</i> , 2015, 45, 385-393.	1.7	6
46	Cystatin C-based <scp>CKD-EPI</scp> Equations and N-Terminal Pro-B-Type Natriuretic Peptide for Predicting Outcomes in Acutely Decompensated Heart Failure. <i>Clinical Cardiology</i> , 2015, 38, 106-113.	0.7	17
47	Unexpected autopsy findings after sudden cardiac death: Cardiovascular myxoedema and endocardial fibroelastosis. <i>International Journal of Cardiology</i> , 2015, 182, 281-283.	0.8	4
48	Comparaci3n de las ecuaciones de filtrado glomerular estimado para determinar la posolog3a de los nuevos anticoagulantes orales para pacientes con fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 497-504.	0.6	31
49	Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn. <i>International Journal of Cardiology</i> , 2015, 187, 517-518.	0.8	13
50	Combined Multimodal Computed Tomography Score Correlates With Futile Recanalization After Thrombectomy in Patients With Acute Stroke. <i>Stroke</i> , 2015, 46, 2517-2522.	1.0	48
51	Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 497-504.	0.4	17
52	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-788.	1.8	36
53	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 696-701.	1.0	39
54	Interleukin-6 as a predictor of cardiovascular events in troponin-negative non-ST elevation acute coronary syndrome patients. <i>International Journal of Clinical Practice</i> , 2014, 68, 294-303.	0.8	13

#	ARTICLE	IF	CITATIONS
55	Red Cell Distribution Width and Additive Risk Prediction for Major Bleeding in Non-ST-segment Elevation Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 830-836.	0.4	5
56	Methods of kidney function assessment in non-valvular atrial fibrillation in the era of new oral anticoagulants. <i>European Journal of Internal Medicine</i> , 2014, 25, e71-e72.	1.0	3
57	Red Cell Distribution Width and Coronary Artery Disease. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 968-969.	0.4	0
58	Amplitud de distribución eritrocitaria y enfermedad coronaria. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 968-969.	0.6	0
59	Renal Impairment in a Real-Life Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). <i>American Journal of Cardiology</i> , 2013, 111, 1159-1164.	0.7	110
60	Heart rate control in chronic heart failure: Resting versus mean heart rate with prolonged ambulatory ECG recording. <i>International Journal of Cardiology</i> , 2013, 170, e45-e47.	0.8	9
61	The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2199-2204.	1.2	171
62	Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 583-591.	0.7	41
63	Renal function measurements and mortality in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 4990-4991.	0.8	6
64	Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 185-192.	0.4	11
65	Interleucina 6 y proteína C reactiva ultrasensible para la predicción de la evolución clínica en síndromes coronarios agudos sin elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 185-192.	0.6	12
66	The prognostic role of the adiponectin levels in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013, 43, 168-173.	1.7	20
67	Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a Real-World Population With Atrial Fibrillation Receiving Anticoagulant Therapy. <i>Chest</i> , 2013, 143, 179-184.	0.4	176
68	Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes. <i>Atherosclerosis</i> , 2013, 227, 313-322.	0.4	87
69	Î ² -Trace Protein: From GFR Marker to Cardiovascular Risk Predictor. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 873-881.	2.2	32
70	Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. <i>Age and Ageing</i> , 2013, 42, 70-75.	0.7	14
71	Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Circulation Journal</i> , 2013, 77, 2088-2096.	0.7	6
72	Î ² -Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. <i>Chest</i> , 2013, 144, 1564-1570.	0.4	12

#	ARTICLE	IF	CITATIONS
73	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 956-960.	1.8	102
74	Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 459-466.	1.4	60
75	Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure. <i>Cardiology</i> , 2012, 122, 158-166.	0.6	67
76	Prognostic Significance of Long-Period Heart Rate Rhythms in Chronic Heart Failure. <i>Circulation Journal</i> , 2012, 76, 2124-2129.	0.7	4
77	Primary Prevention With Aspirin in Type 2 Diabetic Patients. <i>Circulation Journal</i> , 2012, 76, 1333-1334.	0.7	0
78	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1500-1507.	1.9	97
79	Red Blood Cell Distribution Width Adds Prognostic Value for Outpatients With Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 606-612.	0.4	14
80	El ancho de distribución eritrocitaria aporta valor pronóstico adicional en pacientes ambulatorios con insuficiencia cardiaca crónica. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 606-612.	0.6	29
81	Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. <i>American Heart Journal</i> , 2012, 163, 1002-1010.	1.2	72
82	Red blood cell distribution width predicts new-onset anemia in heart failure patients. <i>International Journal of Cardiology</i> , 2012, 160, 196-200.	0.8	35
83	Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1302-1308.	1.7	21
84	Usefulness of β -Trace Protein and Cystatin C for the Prediction of Mortality in Non ST Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2012, 110, 1240-1248.	0.7	21
85	Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. <i>European Journal of Internal Medicine</i> , 2012, 23, 599-603.	1.0	28
86	Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. <i>Thrombosis and Haemostasis</i> , 2012, 107, 51-58.	1.8	13
87	High-Sensitivity Troponin T and Copeptin in Non-ST Acute Coronary Syndromes: Implications for Prognosis and Role of hsTnT and Copeptin in Non-STEACS. <i>Scientific World Journal</i> , The, 2012, 2012, 1-8.	0.8	7
88	Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 718-725.	2.9	228
89	β -Trace Protein and Cystatin C as Predictors of Long-Term Outcomes in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 57, 849-858.	1.2	66
90	Short-Term Variability of Heart Rate Turbulence in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 735-741.	0.7	6

#	ARTICLE	IF	CITATIONS
91	Comparative Prognostic Value of Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Destabilized Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 365-372.	0.4	1
92	Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2011, 107, 259-267.	0.7	185
93	Anabolic Status and Functional Impairment in Men With Mild Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 862-866.	0.7	13
94	An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. <i>Chest</i> , 2011, 139, 1402-1409.	0.4	15
95	Same morphology of ventricular premature complexes triggering repeated ventricular fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010, 28, 95-100.	0.6	2
96	Heart Rate Variability on 7-Day Holter Monitoring Using a Bootstrap Rhythmometric Procedure. <i>IEEE Transactions on Biomedical Engineering</i> , 2010, 57, 1366-1376.	2.5	18
97	Comparison of Detection of Arrhythmias in Patients With Chronic Heart Failure Secondary to Non-Ischemic Versus Ischemic Cardiomyopathy by 1 Versus 7-Day Holter Monitoring. <i>American Journal of Cardiology</i> , 2010, 106, 677-681.	0.7	20
98	Impact of Kidney Dysfunction on Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 214-220.	2.0	34
99	Acute Disabling Low-Back Pain during Intravenous Administration of Amiodarone: Could Intravenous to Oral Switch Therapy Be a Safe Strategy?. <i>Cardiology</i> , 2010, 117, 275-277.	0.6	5
100	Ventricular arrhythmias in Chronic Chagas' Myocardopathy: A case report and brief review of different antiarrhythmic strategies. <i>International Journal of Cardiology</i> , 2010, 138, 88-90.	0.8	2
101	Extrasistolia ventricular desencadenante de la fibrilaci3n ventricular. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 798-801.	0.6	6
102	Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. <i>European Journal of Heart Failure</i> , 2009, 11, 840-846.	2.9	187
103	Usefulness of Serial Monitoring of B-Type Natriuretic Peptide for the Detection of Acute Rejection After Heart Transplantation. <i>American Journal of Cardiology</i> , 2009, 103, 1149-1153.	0.7	29
104	Complementary Prognostic Value of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T in Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2009, 103, 1753-1759.	0.7	88
105	Antithrombotic therapy after coronary stenting in patients with indication for oral anticoagulation. <i>International Journal of Cardiology</i> , 2009, 134, 125-127.	0.8	2
106	Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting. <i>Chest</i> , 2009, 135, 983-990.	0.4	19
107	¿Existe un lugar para levosimend3n en los servicios de urgencias hospitalarios?. <i>Revista Espanola De Cardiologia</i> , 2008, 61, 545-546.	0.6	1
108	Is There a Role for Levosimendan in Hospital Emergency Departments?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 545-546.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Troponin-T Monitoring in Outpatients With Nonischemic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 678-686.	0.4	4
110	Is thrombogenesis related to residual platelet function in ischaemic heart disease?. <i>European Heart Journal</i> , 2008, 29, 3065-3065.	1.0	0
111	Anaemia as predictor of gastrointestinal bleeding in atrial fibrillation patients undergoing percutaneous coronary artery stenting. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 749-751.	0.2	5
112	Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting. <i>Chest</i> , 2008, 134, 559-567.	0.4	117
113	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. <i>European Heart Journal</i> , 2008, 30, 932-939.	1.0	44